Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma (METSLIVER)

December 16, 2019 updated by: Assistance Publique - Hôpitaux de Paris

The Influence of Metabolic Syndrome and Circulating Bile Acid Levels on the Development of Hepatocellular Carcinoma and Biliary Tract Cancers

Increasing rates of highly malignant hepatocellular carcinoma (HCC) and biliary tract cancers (GBTC) observed in Western populations may be related to obesogenic lifestyle factors and their metabolic consequences, such as metabolic syndrome (MetS), inflammation and altered production of bile acids (BA). Such lifestyle behaviours may induce changes in the gut microflora which in turn affect BA profiles, increasing their carcinogenicity. Some elevated BA may be oncogenic in exposed liver, bile ducts and gall bladder. Vertical sleeve gastrectomy may change bile acid composition.

The aims of this study are:

  1. whether specific presurgical bila acid profiles are predictive of efficacy of vertical sleeve gastrectomy, reflective of liver function and metabolic dysfunction;
  2. whether specific presurgical bile acid profiles are predictive of the efficacy of sleeve gastrectomy

Study Overview

Status

Completed

Conditions

Detailed Description

"Increasing rates of highly malignant hepatocellular carcinoma (HCC) and biliary tract cancers (GBTC) observed in Western populations may be related to obesogenic lifestyle factors and their metabolic consequences, such as metabolic syndrome (MetS), inflammation and altered production of bile acids (BA). Such lifestyle behaviours may induce changes in the gut microflora which in turn affect BA profiles, increasing their carcinogenicity. Some elevated BA may be oncogenic in exposed liver, bile ducts and gall bladder. Data from case-control studies show higher blood BA in patients with various liver diseases, but from these designs it is unclear if the differences in BA levels are etiologic or consequential. To date no prospective studies have investigated the role of circulating BA levels in the development of HCC/GBTC, nor any potential interactions with diet, obesity and MetS. Interestingly, Vertical Sleeve Gastrectomy (VSG), an anti-obesity intervention, may alter BA profiles in some patients towards a potentially detrimental composition, but this is largely unexplored.

Project description: This project is composed of two complementary studies designed to explore the role of BA in obesity, liver function and tumourigenesis. The 1st study is a case-control study of hepatobiliary cancers (191 HCC; 266 GBTC; 457 matched controls) nested within a large prospective cohort of Franco-European populations (EPIC, >520,000 subjects) with extensive and detailed dietary/lifestyle data, body size measures and biological samples taken at baseline prior to disease development. The aim of this study is to explore associations between pre-diagnostic MetS markers and BA levels and the risk of HCC and GBTC, and to establish whether the observed associations are modulated, in part, by dietary/lifestyle factors or metabolic dysfunction.

The 2nd study is based on a clinical setting and aims to recruit 100 morbidly obese subjects undergoing VSG to compare their BA and metabolic profiles pre- to 1 year post-surgery. This study is based on observations that post-VSG BA synthesis is increased, but changes in BA composition towards possibly harmful profiles have not previously been studied. It is also hypothesized that the degree of weight loss and metabolic improvement in VSG patients may be related to pre-surgical BA profiles.

In both studies, comprehensive panel of 17 serum BA (primary, secondary, (un)-conjugated, sulphated) and metabolic biomarkers (inflammation, liver function, dyslipidemia, HbA1c, MetS indicators, hepatitis status) will be assessed using validated methods. Study 2 will also assess expression of liver FXR, a BA receptor gene. Statistical Methods: Study 1 will calculate odds ratios and 95% confidence intervals for circulating BA levels/MetS markers in relation to HCC and GBTC risk by multivariable conditional logistic regression, controlling for potential confounding variables and effect modifiers. Receiver operating characteristics (ROC) analyses will be performed to assess a combination of BA and metabolic markers with best performance to prospectively distinguish between cancer cases and controls. In study 2, GLM (repeated measures) ANOVA will be used to compare pre-/post-surgery changes in biomarkers. BA profiles from both studies, will be compared and correlations between BA and other biomarkers, lifestyle and body size measures will be assessed.

Expected results: This project is based on two related concepts. First, that lifestyle behaviours and obesity may alter gut microflora leading to changes in BA metabolism, enhancing production of specific BA known to be cancer promoting. Second, observations of increased BA levels post-VSG surgery, which may improve metabolic function, but some BA may be pro-carcinogenic over the longer term. The project will provide improved understanding of the inter-relations between BA, lifestyle behaviours and metabolic factors and the development of hepatobiliary cancers. It will also identify specific BA most strongly associated with these highly malignant cancers. The findings will contribute to the evidence base for advice on lifestyle and metabolic modifications for cancer prevention. The clinical implications are two-fold. First, the findings will provide insight as to whether BA profiles are predictive of the efficacy of VSG with potential implications in personalized medicine, and second, identified biomarker profiles may be used for more refined risk stratification for development of these cancers and subsequent closer patients' surveillance for early detection "

Study Type

Observational

Enrollment (Actual)

124

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Clamart, France, 92141
        • AP-HP, Antoine Béclère Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who undergo vertical sleeve gastrectomy

Description

Inclusion Criteria:

  • Patients who undergo vertical sleeve gastrectomy

Exclusion Criteria:

  • No liver histology

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients
Patients with morbid obesity and vertical sleeve gastrectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Blood bile acids (micromols per liter)
Time Frame: at one year after surgery
at one year after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hepatic FXR expression
Time Frame: At baseline
Gene of Biliary acids Receptor
At baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

Institut National de la Santé Et de la Recherche Médicale, France
National Cancer Institute, France
Centre International de la Recherche sur le Cancer

Investigators

  • Principal Investigator: Gabriel PERLEMUTER, MD, PhDi, Assistance Publique - Hôpitaux de Paris, Antoine Béclère Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 1, 2016

Primary Completion (ACTUAL)

October 1, 2017

Study Completion (ACTUAL)

December 1, 2018

Study Registration Dates

First Submitted

April 1, 2016

First Submitted That Met QC Criteria

April 5, 2016

First Posted (ESTIMATE)

April 6, 2016

Study Record Updates

Last Update Posted (ACTUAL)

December 17, 2019

Last Update Submitted That Met QC Criteria

December 16, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PRT-K14-038

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe